Trastuzumab-deruxtecan monotherapy (DESTINY-CRC01, HER2+ mCRC)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-TRASTUZUMAB-DERUXTECAN |
|---|
| ID | REG-TRASTUZUMAB-DERUXTECAN-CRC |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Notes
DESTINY-CRC01 Phase II (2021): HER2-amp RAS-WT chemo-refractory mCRC (median 4 prior lines), ORR 45% in IHC 3+/IHC 2+ ISH+ cohort, mPFS 6.9 mo, mOS 15.5 mo. T-DXd is an ADC: trastuzumab + cleavable linker + DXd (DNA topo-I inhibitor exatecan derivative). Bystander effect benefits HER2-heterogeneous tumors. ILD/pneumonitis is the dominant safety signal (~6% all-grade, ~3% Grade ≥3) — baseline + serial lung imaging mandatory. CRC dose 6.4 mg/kg differs from breast/gastric 5.4 mg/kg (DESTINY-CRC01 protocol).
Used By
Indication
IND-CRC-METASTATIC-2L-HER2-AMP-T-DXD- IND-CRC-METASTATIC-2L-HER2-AMP-T-DXD